Manoussos Perros
Chief Executive Officer at ENTASIS THERAPEUTICS HOLDINGS INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nicholas G. Galakatos | M | 66 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 8 years |
| Mike Gutch | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.
Entasis Therapeutics Ltd.
 Entasis Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., Entasis Therapeutics Ltd. is a British pharmaceutical company founded in 2015. The company is based in Altrincham, UK and manufactures and distributes pharmaceutical products. | 7 years |
| Andrew J. Staples | M | 54 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 years |
| David Hastings | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 6 years |
| James Topper | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 8 years |
| Heather Preston | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 7 years |
| Heather Behanna | M | 49 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 7 years |
| David Meek | M | 59 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 years |
| Ruben Tommasi | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | 13 years |
| John Mueller | M | 64 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | 13 years |
| Richard Levin | M | 77 |
Yale University
| 31 years |
| David Altarac | M | 63 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 years |
| Kyle Dow | M | - |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | - |
| Pavel Raifeld | M | 40 | 2 years | |
| Anna Diaz Triola | F | - | 3 years | |
| Marianne Zhen | F | 55 | 2 years | |
| Louise M. Dembry | M | - |
Yale University
| 31 years |
| Elan Gandsman | M | 82 |
Yale University
| 31 years |
| Matthew Ronsheim | M | 52 | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gregory Norden | M | 66 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | - |
| Simon Lowth | M | 61 |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | - |
| Swan Chang | M | - |
Yale University
| 4 years |
| Josh Duhl | M | - |
Yale University
| 5 years |
| Sarah P. Payne | F | - |
Yale University
| 4 years |
| Howard Mayer | M | 61 | 3 years | |
| Anders Olof Adolf Ekblom | M | 70 |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | 7 years |
| Shakil Waiz Ahmed | M | - |
Yale University
| 6 years |
| Bing Yuan | M | 55 |
Yale University
| 5 years |
| Robert Hopfner | M | 51 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | - |
| Gao Wang | M | 57 |
Yale University
| 5 years |
| Joseph Patt | M | - |
Yale University
| 4 years |
| Eric W. Kimble | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 1 years |
| Blaise Coleman | M | 50 |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | 4 years |
| So-Young Kim | M | 57 |
Yale University
| 3 years |
| Thomas Dyrberg | M | 69 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | - |
| Ophir Klein | M | - |
Yale University
| 7 years |
| Felton Jenkins | M | - |
Yale University
| 3 years |
| Robin Isaacs | M | 65 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 4 years |
| Linda Lorimer | F | 72 |
Yale University
| - |
| Kristie Wagner | F | 57 | - | |
| Xu Hui Shen | M | 45 |
Yale University
| 6 years |
| Zachary Krug | M | - |
Yale University
| 4 years |
| Robert Kinderman | M | 48 |
Yale University
| 4 years |
| Tom Newell | M | - |
Yale University
| 4 years |
| Jaime R. Harrison | M | - |
Yale University
| 4 years |
| Daniel Joseph Duggan | M | - |
Yale University
| 4 years |
| Dwight S. Yoo | M | - |
Yale University
| 4 years |
| Sara Murtadha Jaffar Sulaiman | F | 53 |
Yale University
| 4 years |
| Nell Breyer | F | - |
Yale University
| 4 years |
| Carrie Mermelstein | F | - |
Yale University
| 4 years |
| Ke Wei Xie | M | 63 |
Yale University
| 3 years |
| Jack Taylor Thompson | M | 52 |
Yale University
| 4 years |
| Simon Duxbury | M | - |
Yale University
| 4 years |
| Gang-Shik Choi | M | 64 |
Yale University
| 3 years |
| Kenneth Toshima | M | - |
Yale University
| 2 years |
| Colin Savage | M | - |
Yale University
| 4 years |
| Anthony Philippakis | M | 48 |
Yale University
| 4 years |
| Quentin Koffey | M | 46 |
Yale University
| 4 years |
| Brent Irvin | M | 52 |
Yale University
| 1 years |
| Erin Lavelle | F | 46 |
Yale University
| 3 years |
| Zach Scheiner | M | 47 |
Yale University
| 4 years |
| Yukie Nakano | M | 59 |
Yale University
| 3 years |
| Nathan R. Harrington | M | 57 |
Yale University
| 2 years |
| Frank Fabozzi | M | 76 |
Yale University
| 17 years |
| Massimiliano Marzo | M | - |
Yale University
| 2 years |
| Shail Khiyara | M | 57 |
Yale University
| 2 years |
| Umut Ergun | M | - |
Yale University
| 4 years |
| Xiao-Hong Jing | F | - |
Yale University
| 3 years |
| John Ellertson Peetz | M | - |
Yale University
| 4 years |
| Bengt Robert Holmström | M | 75 |
Yale University
| 9 years |
| Andy Toburen | M | 52 |
Yale University
| 4 years |
| Martin Hale | M | 52 |
Yale University
| 4 years |
| Greg Bond | M | 53 |
Yale University
| 4 years |
| Yogesh Vishnu Borkar | M | - |
Yale University
| 2 years |
| Kent E. Radspinner | M | - |
Yale University
| 2 years |
| David Stephen Charney | M | - |
Yale University
| 4 years |
| Ryan A. Rauch | M | - |
Yale University
| 4 years |
| Brian Charles Osias | M | - |
Yale University
| 4 years |
| Fernando Vigil | M | - |
Yale University
| 4 years |
| Rich Edelman | M | - |
Yale University
| 4 years |
| Nicholas G. Demmo | M | - |
Yale University
| 4 years |
| Damon S. Judd | M | - |
Yale University
| 4 years |
| Zheng Ma | M | 57 |
Yale University
| 3 years |
| Pawel Chudzicki | M | - |
Yale University
| 4 years |
| Hironori Kamemoto | M | - |
Yale University
| 3 years |
| Jon Levinson | M | - |
Yale University
| 4 years |
| Ingrid Kiefer | F | - |
Yale University
| 5 years |
| John V. Calce | M | - |
Yale University
| 4 years |
| Emily Rabin Cowan | F | - |
Yale University
| 4 years |
| Charles Lazor | M | - |
Yale University
| 1 years |
| Xiang Liu | M | - |
Yale University
| 3 years |
| Charles C. Hale | M | 52 |
Yale University
| 4 years |
| Seth Seifman | M | - |
Yale University
| 4 years |
| Jay Michaelson | M | - |
Yale University
| 3 years |
| Jerry B. Pence | M | - |
Yale University
| 4 years |
| David Ira Schamis | M | 50 |
Yale University
| 4 years |
| Peter Beinart | M | - |
Yale University
| 4 years |
| Corby Reese | M | - |
Yale University
| 10 years |
| steve kraus | M | - |
Yale University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 96 | 96.97% |
| Sweden | 5 | 5.05% |
| United Kingdom | 1 | 1.01% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Manoussos Perros
- Personal Network
